What Euretos does

Euretos B.V. is a Dutch bioinformatics company founded in 2012 and headquartered at Leiden Bio Science Park, with a North American office in Boston. It sells the Euretos AI Platform (EAIP), an enterprise SaaS product whose flagship is Disease Atlas — a cell-type-resolved, evidence-graded map of disease biology covering approximately 34,000 diseases, built from a FAIR-integrated knowledge base harmonising 200+ biomedical databases, 100 million publications, 2.5 million drug patents and 3,500 single-cell RNA sequencing cell-type profiles. The platform's core methodology is a four-pipeline causal-inference architecture — Mendelian randomisation plus perturbation concordance, tractability scoring (antibody/small molecule/ADC/bispecific/T-cell engager), per-organ safety assessment, and modality scoring — explicitly designed to rank therapeutic targets by causal and molecular evidence rather than by literature mentions, with calibrated probabilities reporting AUCs of 0.947, 0.917 and 0.885 against 2,587 completed clinical trials.

Euretos serves pharmaceutical and biotechnology enterprises (named customers include H. Lundbeck, Teva, Genmab, Janssen, AstraZeneca, Boehringer Ingelheim) plus academic institutions, monetising through tiered subscriptions (Trial free, Academic Pro €1,200/year, Academic Team €2,400/year, Professional €3,600/year, Enterprise custom) and separate professional-services engagements. The go-to-market combines enterprise field sales for pharma with a community-led academic PLG funnel and event-driven presence at EMBL, BioEurope and Innovation for Health. Distribution is direct SaaS with API access under a separate licence, GDPR-compliant EU hosting, and SSO/custom integrations for Enterprise customers.

The company operates without disclosed external VC funding, generating revenue from a mix of subscription and consulting, and participates in major public consortia (Dutch National Growth Fund €325M cancer initiative, Horizon 2020 €4M TrainCKDis, €10M personalised-hypertension grant). Leadership comprises co-founders Aram Krol (CEO), Arie Baak and Albert Mons, with Kees Albers as Chief Scientific Officer.

Name

Euretos

Legal name

Euretos B.V.

Website

https://euretos.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

Euretos B.V. is a Dutch bioinformatics company that sells the Euretos AI Platform and Disease Atlas — a cell-type-resolved causal-inference platform for therapeutic target discovery and validation — to pharmaceutical, biotechnology and academic customers worldwide.

Ownership category

akta.pro rank

Product category

Bioinformatics & Drug Discovery Software

NAICS

Software Publishers (5132)

SIC

Services-Prepackaged Software (7372)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industry

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

Keywords

• Target discovery platform
• Biomarker identification software
• Disease biology analytics
• Causal inference platform
• Drug target validation

Headquarters

HQ city

Utrecht

HQ country

Netherlands

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations

Revenue model

1. SaaS Platform Subscription: Annual subscription model with tiered pricing based on user count and feature access. Includes Disease Atlas, Search, Relation Map applications plus Target and Cancer Workflows. License periods typically one year with 25% discount for annual payment.
2. Professional Services: Consulting projects with defined endpoints, milestones, deliverables, budgets and fees. Custom project work for specific client needs delivered under separate Service Agreements.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

Core offering

Euretos sells an AI-driven disease biology platform (the Euretos AI Platform / EAIP) anchored by the Disease Atlas, a cell-type-resolved map of approximately 34,000 diseases that ranks therapeutic target candidates by causal and molecular evidence rather than by literature mentions. It bundles several applications (Search, Analytics, Sets, Relation Map), target-oriented workflows (Identification, Ranking, Assessment), and specialised Cancer Workflows, with access provided via tiered SaaS subscriptions and complementary custom professional services engagements.

Product overview

Euretos offers the Euretos AI Platform (EAIP) as a unified software platform for data-driven translational research in drug discovery. The platform is built around the Disease Atlas product—a cell-type-resolved map of disease biology covering approximately 34,000 diseases—that serves as the primary interface for target discovery, ranking, and assessment. Multiple applications run on the EAIP including Analytics, Search, Sets, and Relation Map, which leverage the integrated knowledge base. Target-oriented workflows (Target Identification, Target Ranking, Target Assessment) guide users from disease understanding through candidate prioritization to defensible programme decisions. Cancer-specific workflows provide specialized functionality for oncology research. The platform integrates over 200 biomedical databases, 100 million publications, and 3,500 single-cell profiles, with all evidence traceable to primary biological data rather than literature aggregation. Access is provided through tiered subscriptions (Trial, Academic Pro, Academic Team, Professional, Enterprise) with the API available as a separate license.

Differentiator

Problem solved

Functional benefit

Brands

• Disease Atlas: A navigable, evidence-graded map of disease biology built from primary biological data, resolved to cell type across 34,000 diseases. It provides translational researchers direct access to disease drivers, therapeutic target candidates, and causal evidence.

Products and services

• Disease Atlas A navigable, evidence-graded map of disease biology built from primary biological data and resolved to cell type across approximately 34,000 diseases, enabling translational researchers to identify therapeutic target candidates ranked by causal and molecular evidence across six dimensions (causal, mechanistic, expression, network, tractability, safety), each resolved to the cell types where disease operates.
• Euretos AI Platform (EAIP) The core software platform that includes the base platform and integrated data, the API, and specific applications such as Search, Analytics, Sets, and Relation Map; the umbrella product under which all applications and workflows operate.
• Target Identification Workflow A workflow for identifying novel therapeutic target candidates using causal evidence from Mendelian randomisation, perturbation biology, and single-cell expression data, delivered as part of the EAIP subscription.
• Target Ranking Workflow A workflow that ranks the full protein-coding genome per disease across five scored dimensions (biology, development, druggability, safety, and literature), producing decomposed scores showing what drives each candidate's rank.
• Target Assessment Workflow A workflow for building a six-panel assessment covering disease mechanisms, genetic evidence, network context, expression relevance, safety, and tractability for any gene-disease pair.
• Cancer Workflows Specialized cancer-specific workflows including target identification in cancer, dual expressed cancer targets, single cell study viewer, cancer cell line finder, and antibody finder; requires additional license fee beyond the standard platform subscription.
• Euretos AI Platform API An Application Programming Interface providing programmatic access to EAIP functionality including data search, set uploads, analytics execution, and relation map creation; requires an explicit separate API license for back-end data access.
• Professional Services Custom consulting projects with defined endpoints, milestones, deliverables, budgets and fees, delivered under separate Service Agreements to address specific target discovery, indication selection, or biomarker research needs of individual clients.

Quantifiable outcome

• 91.5% clinical trial success rate for top-decile Disease Atlas targets (vs 50% bottom decile; 1.8x lift)
• +3 more outcomes

Named customers11 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

Integration17 records

AI capability6 records

Feature7 records

Partnerships

Eight partnerships are on record, tiered minor and core.

• HealxminorStrategic or Co-development Partner · 1 July 2025July 2025 alliance with SCI Ventures for AI-powered paralysis therapies.
• XtalPiminorStrategic or Co-development Partner · 1 July 2025July 2025 partnership with Pfizer to expand AI-driven drug discovery.
• Metabolomics Implementation NetworkcoreStrategic or Co-development Partner · 10 March 2017European consortium launched at University of Leiden to apply FAIR data principles in metabolomics. Includes EMBL-EBI, Imperial College London, Leiden University, Oxford University, CIRRMP, CNRS, University of Jena, Janssen Pharmaceuticals, DSM, the Hyve, and Euretos. Aims to improve insight in disease onset and progression, diagnostics, treatment options, and personalised medicine.
• Personalised Hypertension Treatment ConsortiumcoreStrategic or Co-development PartnerLarge research consortium including Euretos awarded €10 million grant for personalised hypertension treatment research.
• TrainCKDis ConsortiumcoreStrategic or Co-development PartnerHorizon 2020 funded consortium of 19 European research institutions, pharmaceutical companies and service providers focused on Chronic Kidney Disease (CKD). Euretos is one of 10 associated partners working with Leiden University Medical Centre (one of 9 main partners). TrainCKDis provides multidisciplinary training programme for young scientists developing solutions for CKD.
• Dutch National Growth Fund Cancer ResearchcoreStrategic or Co-development PartnerDutch National Growth Fund invested €325 million in accelerating cancer drug development, with Euretos participating in the initiative.
• HollandBIOminorChannel Partner/ Reseller/ DistributorEuretos joined HollandBIO as its first AI technology provider, supporting biotech community access to AI-driven drug discovery tools.
• EMBLcoreStrategic or Co-development PartnerSelected to present at EMBL Target Validation using Genomics and Informatics conference. Euretos has been presenting at EMBL events since 2016 as academic and industry partners are equally represented.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Exscientia: AI-native pharma combining target discovery, molecule design, and precision medicine with a pharma partnership model; competes with Euretos in AI-enabled drug discovery enterprise deals with similar pharma accounts.
• BenevolentAI: AI-driven drug discovery company with a knowledge graph and machine learning platform for target identification and drug development, targeting the same pharma and biotech customers as Euretos with similar enterprise sales motions.
• Insitro: Machine learning-driven drug discovery combining induced pluripotent stem cell disease models with ML for target identification; targets similar large-pharma partnerships with focus on disease biology understanding.
• Recursion Pharmaceuticals: AI-driven biotech combining high-throughput biology with machine learning for target discovery and indication expansion; comparable in focusing on causal inference and biology-first target prioritization for pharma partners.
• Atomwise: AI small-molecule drug discovery platform using deep learning for hit identification and lead optimization; comparable in deploying AI-driven target-to-lead workflows with pharma and biotech customers.
• Owkin: AI for biomedical research integrating multi-omic and clinical data for target discovery and biomarker identification; comparable in serving pharma enterprise customers with AI-driven translational research.
• XtalPi: AI + physics-based drug discovery platform partnering with Pfizer for AI-driven discovery; operates in the same AI drug discovery enterprise market with overlapping capabilities in target identification and lead design.
• Schrödinger: Computational drug discovery platform combining physics-based simulation with ML for target assessment and lead optimization; serves the same pharma/biotech customer base with overlapping target ID and prioritization use cases.

Broad incumbents

• Clarivate: Broader life-sciences intelligence and analytics provider with drug discovery, competitive intelligence, and patent analytics products targeting the same enterprise pharma buyers; competes indirectly in target intelligence and landscape analysis.
• QIAGEN (Ingenuity Pathway Analysis): Broader life sciences tools and bioinformatics provider with pathway analysis, knowledge bases, and clinical genomics solutions; comparable as a competing biology knowledge platform for target discovery and interpretation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/euretos
• LinkedInlinkedin.com/company/euretos

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Euretos